Primary Hyperoxaluria - Epidemiology Forecast - 2032

This ‘Primary Hyperoxaluria (PH)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Primary Hyperoxaluria (PH) historical and forecasted epidemiology as well as the Primary Hyperoxaluria (PH) epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Primary Hyperoxaluria (PH) Understanding

Primary Hyperoxaluria (PH) Overview

Primary Hyperoxaluria (PH) is a rare genetic disease caused by deficiencies in glyoxylate metabolism. Broadly, the PH is inherited in an autosomal recessive fashion and divided into three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). The kidney is the prime target for oxalate deposition, which leads to end-stage renal disease in a significant number of cases.

Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs). Phenotypically the disease is characterized by the recurrent formation of kidney stones and nephrocalcinosis, resulting in the gradual decline of kidney function. Once renal function deteriorates, excessive oxalate can no longer be eliminated through the urine, and thus calcium oxalate crystals precipitate in various tissues, leading to a devastating multiorgan disease called systemic oxalosis.

Primary Hyperoxaluria (PH) Diagnosis

Diagnosis of PH is based upon identification of characteristic symptoms (e.g. chronic stone formation), a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. Children with nephrocalcinosis or kidney stones should be screened for PH. PH may be suspected in individuals with a history of recurrent kidney stones and/or nephrocalcinosis. Because these conditions are rare, there may be a delay from symptom onset to diagnosis. Investigation for PH includes measuring urine and plasma oxalate levels, ruling out other causes of high oxalate levels (dietary or enteric hyperoxaluria), molecular genetic testing for mutations, and detecting the presence of kidney stones and examining their composition.

Primary Hyperoxaluria (PH) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Primary Hyperoxaluria, Diagnosed Prevalent Cases of Primary Hyperoxaluria, Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, and Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Primary Hyperoxaluria (PH) Detailed Epidemiology Segmentation

• The total prevalent population of PH in 7MM was 11,948 in 2021, which is expected to increase at a CAGR of 0.66%.
• The US accounted for the highest prevalent population of PH among 7MM with 8,773 cases in 2021.
• The estimates suggest a higher diagnosed prevalence of PH in the United States with 2,327 diagnosed cases in 2021.
• Among the European countries, the UK had the highest diagnosed prevalent cases of PH with 202 cases, followed by Germany which had diagnosed prevalent population of 180, in 2021. On the other hand, Spain had the lowest diagnosed prevalent population (90 cases).
• Epidemiology assessed for PH showed that Japan accounts for approximately 2.55% of the total 7MM diagnosed prevalent population, which approximates 80 cases in 2021 which is expected to increase by 2032.
• The estimates suggest higher diagnosed prevalence of PH Type 1 throughout the 7MM. In the US, out of total diagnosed prevalent cases of PH; 1,629 were occupied by PH Type 1 alone, in the year 2021.
• In 2021, out of total diagnosed prevalent cases in Japan, males and females contributed to 47 and 33 cases, respectively.

Scope of the Report

• The report covers the descriptive overview of Primary Hyperoxaluria (PH), explaining its causes, signs, and symptoms, pathophysiology, and diagnosis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden.
• The report provides the segmentation of the disease epidemiology for 7MM by segmented by Prevalent Cases of Primary Hyperoxaluria, Diagnosed Prevalent Cases of Primary Hyperoxaluria, Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, and Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria.

Report Highlights

• 10-Year Forecast of Primary Hyperoxaluria (PH)
• 7MM Coverage
• Prevalent Cases of Primary Hyperoxaluria
• Diagnosed Prevalent Cases of Primary Hyperoxaluria
• Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
• Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
• Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria

Key Questions Answered

• What are the disease risk, burdens, and unmet needs of Primary Hyperoxaluria (PH)?
• What is the historical Primary Hyperoxaluria (PH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Primary Hyperoxaluria (PH) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Primary Hyperoxaluria (PH)?
• Out of the countries mentioned above, which country would have the highest patient population of Primary Hyperoxaluria (PH) during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Primary Hyperoxaluria (PH) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Primary Hyperoxaluria (PH) epidemiology.
• Quantify patient populations in the 7MM Primary Hyperoxaluria (PH) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the type-specific cases of Primary Hyperoxaluria (PH) that present the best opportunities for Primary Hyperoxaluria (PH) therapeutics in each of the markets covered.
• The Primary Hyperoxaluria (PH) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Primary Hyperoxaluria (PH) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032